Mediastinal Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mediastinal Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Update: Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma [Phase 3]
Phase 3 trial evaluating nivolumab in combination with chemo-immunotherapy for newly diagnosed primary mediastinal large B-cell lymphoma is …
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
This document provides a long-term follow-up update on allogeneic gamma delta CAR T cell therapy. The trial covers several B-cell lymphoma i…
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 study evaluating ALX148 in combination with Rituximab and Lenalidomide for various B-cell non-Hodgkin lymphomas, with the trial …
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy [Phase 2]
Phase 2 clinical trial evaluating a CD3xCD20 bispecific antibody for relapse/refractory B-cell non-Hodgkin lymphomas after CAR-T therapy has…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating anakinra to prevent severe CAR-T cell-related encephalopathy in patients with recurrent or refractory diffuse large…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma [Phase 1]
A Phase 1 exploratory study evaluated CD19-targeted CAR T cells (BZ019) in relapsed/refractory B-cell lymphomas, including diffuse large B-c…
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation [Phase 2]
Phase 2 intergroup trial evaluating DA-EPOCH-R with Rituximab in children and adolescents with primary mediastinal large B-cell lymphoma has…
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65) [Phase 2]
Phase 2 study evaluating pembrolizumab coformulated with berahyaluronidase alfa (MK-3475A) in relapsed or refractory classical Hodgkin lymph…
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas [Phase 2]
Phase 2 study evaluating acalabrutinib plus lisocabtagene maraleucel (Liso-Cel) in refractory/relapsed aggressive B-cell lymphomas, includin…
-
CLINICAL_TRIALS trial_result · 2026-01-13Clinical Trial Update: Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial assessing pembrolizumab with external beam radiation therapy in relapsed or refractory non-Hodgkin lymphoma; the study (NCT032…
-
CLINICAL_TRIALS trial_result · 2025-12-24Clinical Trial Update: Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study
A multicenter retrospective study on primary mediastinal large B-cell lymphoma (PMBCL) has been completed, reporting observational findings …
-
CLINICAL_TRIALS trial_result · 2025-12-09Clinical Trial Update: Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) [NA]
Clinical trial update on adaptive bridging radiotherapy for relapsed/refractory B-cell lymphomas prior to CAR-T therapy; the study status is…
-
CLINICAL_TRIALS trial_result · 2025-10-14Clinical Trial Update: Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies [EARLY_Phase 1]
The document summarizes a Phase 1 trial of dose-adjusted EPOCH-R for mature B-cell malignancies, including Diffuse Large B-Cell Lymphoma, Po…
-
CLINICAL_TRIALS trial_result · 2025-10-08Clinical Trial Update: Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the combination of acalabrutinib with anti-CD19 CAR T-cell therapy for various B-cell lymphomas, in…
-
CLINICAL_TRIALS trial_result · 2025-08-24Clinical Trial Update: 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers [Phase 1]
This is a Phase 1 clinical trial update for a CAR T cell therapy (19(T2)28z1xx) in various B-cell cancers. The study is sponsored by Memoria…
-
CLINICAL_TRIALS trial_result · 2025-08-11Clinical Trial Update: ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies [Phase 1]
Acepodia Biotech's Phase 1 trial of ACE1831 in adults with relapsed/refractory CD20-expressing B-cell malignancies is currently recruiting a…
-
CLINICAL_TRIALS trial_result · 2025-07-16Clinical Trial Update: Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma
A completed follow-up study evaluating a CD19 CAR-T cell therapy engineered to express IL7 and CCL19 for relapsed or refractory B-cell lymph…
-
CLINICAL_TRIALS trial_result · 2025-06-12Clinical Trial Update: Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating dose-adjusted EPOCH chemotherapy plus Rituximab in previously untreated aggressive non-Hodgkin lymphoma has complet…
-
CLINICAL_TRIALS trial_result · 2025-05-16Clinical Trial Update: Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating dendritic cell therapy with cryosurgery and pembrolizumab in various Non-Hodgkin lymphoma subtypes, w…
-
CLINICAL_TRIALS trial_result · 2025-04-06Clinical Trial Update: A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33) [Phase 1]
Phase 1 study of pembrolizumab (Keytruda) in relapsed or refractory primary mediastinal large B-cell lymphoma has completed enrollment, with…
-
CLINICAL_TRIALS trial_result · 2025-02-10Clinical Trial Update: A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) [Phase 2]
A Phase 2 study of pembrolizumab (MK-3475) in relapsed or refractory classical Hodgkin lymphoma and relapsed/refractory primary mediastinal …
-
CLINICAL_TRIALS trial_result · 2025-01-28Clinical Trial Update: Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma [Phase 2]
Phase 2 study evaluating anakinra to reduce CAR-T–related toxicity in patients with relapsed or refractory diffuse large B-cell lymphoma has…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas [Phase 2]
Phase 2 trial evaluating nivolumab with or without varlilumab in relapsed or refractory aggressive B-cell lymphomas, including multiple DLBC…
-
CLINICAL_TRIALS trial_result · 2024-08-26Clinical Trial Update: Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 study evaluating PolaR-ICE (polatuzumab vedotin, rituximab, ifosfamide, carboplatin, etoposide) as initial salvage therapy for relap…
-
CLINICAL_TRIALS trial_result · 2024-08-21Clinical Trial Update: ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) [Phase 1]
The ENABLE-1 Phase 1 trial investigates Toll-like receptor signaling to enhance B-cell lymphoma CAR-T therapy, with the study currently list…